<table>
<thead>
<tr>
<th>Name</th>
<th>African Network for Drug and Vaccine Innovation (ANDI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established</td>
<td>2008, transferred to Africa in 2011</td>
</tr>
<tr>
<td>Headquarters</td>
<td>Addis Ababa, Ethiopia</td>
</tr>
</tbody>
</table>

**Mandate**

ANDI supports and promotes African-led health product innovation for the discovery, development and delivery of drugs, diagnostics and other medical devices and vaccines for diseases that disproportionately affect developing countries, especially in Africa. The vision of ANDI is to create a sustainable platform for health R&D and innovation in Africa to address the continent’s health challenges in a sustainable way. The African Innovation Fund (AIF) is embedded within the financial structure of ANDI, but is yet to be operationalized.

ANDI was set up as a project under the auspices of the WHO through the Special Programme for Research and Training in Tropical Diseases (TDR), Regional Office for Africa (AFRO) and Regional Office for Eastern Mediterranean (EMRO), along with the African Development Bank (AfDB), the European Union (EU) and several national African institutions.

**Founding document**

WHO Resolution WHA62.16

The framework to drive health product innovation, of which ANDI is a part, is derived from the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI) (WHA.61.21). A strategic and business plan for ANDI was developed in 2009.

**Legal entity**

ANDI was initially hosted by the United Nations Economic Commission for Africa (UNECA) in Addis Ababa, Ethiopia. The hosting arrangement is now being transferred to the UN Office for Project Services (UNOPS) also in Addis Ababa. ANDI is expected to function as an Intergovernmental Organization.

**Membership**

ANDI is a pan-African initiative. The ANDI Board is discussing possible future membership by African countries based on annual contribution.

**Governance**

Main governing body: The ANDI Board

http://www.andi-africa.org/index.php/aboutus/governance/andi-board

There are three structures that each play a different role in ANDI’s governance. These are the Board, the Scientific and Technical Advisory Committee (STAC), and the host agency UNECA.

The Board is the highest governing body of ANDI. It comprises representatives from North, South, East, West and Central African regions, independent health experts, the African Diaspora and key institutional partners including the host agency, WHO and AfDB. The STAC is an independent body that provides technical support to the ANDI Board and Secretariat. The STAC provides an annual review of ANDI’s technical activities and makes recommendations. It also supports the transparent review, selection and implementation of projects. The host agency provides administrative oversight of ANDI.

**Diseases and technologies covered**

Technologies: medicines, vaccines, diagnostics and other medical devices as well as health tools based on traditional medicine

Disease areas: Diseases that disproportionately affect the African continent, including Type II and Type III, as well as the special needs of developing countries with Type I diseases, as defined in the GSPA-PHI

**Funding**

Presently ANDI is supported through voluntary contributions by various stakeholders.

Potential sources of funding include traditional donor-based support and innovative health financing.

The host agency holds a Trust Fund where contributions are deposited and used for ANDI activities following the administrative processes of the host agency. ANDI is actively seeking donations. The main challenge for ANDI at present is financial and human resources. ANDI obtains funding from the EU and ongoing support from WHO through TDR, AFRO and EMRO as well as support from the African Development Bank. The Nigerian government has recently made a financial commitment to ANDI.

**Experience in funding and managing R&D**

Funding R&D:

Funding is one of the core R&D activities of ANDI. R&D projects are funded and supported with portfolio management. One major objective is to drive project funding for the African research networks, including capacity building and support for infrastructure. In addition, ANDI brokers partnerships in support of health innovation in Africa.

Managing R&D:
ANDI uses an innovative network-based approach to manage R&D and capacity building. This is supported by a pan-African network of Centers of Excellence (CoEs) developed by ANDI based on a set of criteria. Once a project has been chosen for medicine R&D, CoEs are selected to support the project and capacity is built as part of the project. ANDI focuses on addressing Africa’s unmet disease needs through collaboration with African researchers, North-South and South-South partnerships. It supports the formation of research networks composed of research centers located in Africa that are engaged in a specific research project. Each of these projects drives the development of multiple potential health products (compounds, leads, platforms, etc.) by moving them from discovery to clinical trials and manufacturing for access.


|--------------------------------------------------|--------------------------------------------------------------------------------------------------|